Clinical Trial Update: Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

Open-label extension study of evolocumab in adults with hyperlipidemia and mixed dyslipidemia completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia and Mixed Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2019-06-11